Evidence map›Paper›PMID 38925013›Full record

ArticleEuropean journal of medicinal chemistry2024

Synthesis and biological characterization of an orally bioavailable lactate dehydrogenase-A inhibitor against pancreatic cancer.

Horrick Sharma, Somrita Mondal, Uzziah Urquiza, Colter Esparza, Seth Bartlett, Landon Santa-Pinter, Hanna Hill, Madalyn White, Pragya Sharma, Lerin Luckett-Chastain and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Recent progress in small molecules targeting the acidic tumor microenvironment.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Horrick SharmaDepartment of Pharmaceutical Sciences, College of Pharmacy, Southwestern Oklahoma State University, Weatherford, OK, USA. Electronic address: horrick.sharma@swosu.edu.
Somrita MondalDepartment of Pharmaceutical Sciences, College of Pharmacy, Southwestern Oklahoma State University, Weatherford, OK, USA.
Uzziah UrquizaDepartment of Biological & Biomedical Sciences, Southwestern Oklahoma State University, Weatherford, OK, USA.
Colter EsparzaDepartment of Biological & Biomedical Sciences, Southwestern Oklahoma State University, Weatherford, OK, USA.
Seth BartlettDepartment of Pharmaceutical Sciences, College of Pharmacy, Southwestern Oklahoma State University, Weatherford, OK, USA.
Landon Santa-PinterDepartment of Pharmaceutical Sciences, College of Pharmacy, Southwestern Oklahoma State University, Weatherford, OK, USA.
Hanna HillDepartment of Biological & Biomedical Sciences, Southwestern Oklahoma State University, Weatherford, OK, USA.
Madalyn WhiteDepartment of Biological & Biomedical Sciences, Southwestern Oklahoma State University, Weatherford, OK, USA.
Pragya SharmaDepartment of Biological & Biomedical Sciences, Southwestern Oklahoma State University, Weatherford, OK, USA.
Lerin Luckett-ChastainDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
Anne CooperProtein Structure and X-ray Crystallography Laboratory, The University of Kansas, Lawrence, KS, USA.
Mohammad RaselProtein Structure and X-ray Crystallography Laboratory, The University of Kansas, Lawrence, KS, USA.
Philip GaoProtein Production Group, The University of Kansas, Lawrence, KS, USA.
Kevin P BattaileNew York Structural Biology Center, Upton, NY, USA.
Surendra K ShuklaDepartment of Oncology Science, OU College of Medicine, Oklahoma City, USA.
Scott LovellProtein Structure and X-ray Crystallography Laboratory, The University of Kansas, Lawrence, KS, USA.
Michael A IhnatDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, USA.

Funding

Proteomics CoreP20GM103447 · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2025 to 2025
$4.2M
NIGMS NIH HHS P20 GM103447NIH HHS S10 OD030394
6 · The paper itself

Abstract

Lactate dehydrogenase-A (LDHA) is the major isoform of lactate dehydrogenases (LDH) that is overexpressed and linked to poor survival in pancreatic ductal adenocarcinoma (PDAC). Despite some progress, current LDH inhibitors have poor structural and physicochemical properties or exhibit unfavorable pharmacokinetics that have hampered their development. The present study reports the synthesis and biological evaluation of a novel class of LDHA inhibitors comprising a succinic acid monoamide motif. Compounds 6 and 21 are structurally related analogs that demonstrated potent inhibition of LDHA with IC

Indexed as

Antineoplastic AgentsCell ProliferationEnzyme InhibitorsPancreatic NeoplasmsAdministration, OralAnimalsBiological AvailabilityCell Line, TumorDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansL-Lactate DehydrogenaseMiceModels, MolecularMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsEnzyme InhibitorsL-Lactate DehydrogenaseLactateLactate Dehydrogenase-AOXPHOSPancreatic cancerPharmacokineticsSmall molecule inhibitor

Identifiers

PMID38925013
PMCPMC12131164

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.